{
    "clinical_study": {
        "@rank": "1717", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      Assess the safety and long-term efficacy of monoclonal factor IX concentrate in patients\n      with factor IX deficiency."
        }, 
        "brief_title": "Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency", 
        "condition": [
            "Hemophilia B", 
            "Factor IX Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemophilia B", 
                "Hemophilia A"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive monoclonal factor IX replacement therapy as inpatients. Patients with a\n      satisfactory response receive further therapy as needed for bleeding for up to 36 months at\n      home."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        Patients with factor IX deficiency."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": "3", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004801", 
            "org_study_id": "199/11956", 
            "secondary_id": "UNCCH-621"
        }, 
        "intervention": {
            "intervention_name": "monoclonal factor IX replacement therapy", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "hematologic disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Gilbert C. White", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004801"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of North Carolina", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 1992", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1998"
    }, 
    "geocoordinates": {}
}